Literature DB >> 28673890

Rates of Seizure Freedom After Surgical Resection of Diffuse Low-Grade Gliomas.

Phillip A Bonney1, Lillian B Boettcher2, Joshua D Burks2, Cordell Baker2, Andrew K Conner2, Tats Fujii3, Vivek A Mehta3, Robert G Briggs2, Michael E Sughrue2.   

Abstract

OBJECTIVE: Patients with diffuse low-grade gliomas (DLGGs) typically present with seizures. We sought to review the neurosurgical literature for seizure outcome after resection of these tumors.
METHODS: Using PubMed, we identified surgical series reporting seizure freedom rates for grade II astrocytoma, oligoastrocytoma, and oligodendroglioma. Inclusion criteria included seizure outcomes reported specifically for DLGGs and at least 10 patients with follow-up data.
RESULTS: Twelve articles met the inclusion criteria. The median seizure-free rate after surgery in these patients was 71%, with an interquartile range of 64%-82%. In 10 studies, more than 60% of patients were seizure free. Studies used varying reporting times for seizure outcome determination. In the 6 studies that reported postoperative antiepileptic medication use, 5%-69% of seizure-free patients were weaned off these agents (median, 32%). The durability of seizure freedom has not been clearly studied to date. The most commonly reported prognostic factor for seizure freedom after resection was increasing extent of resection.
CONCLUSIONS: Among articles reporting seizure outcomes after resection of DLGG, the median seizure-free rate was 71% (interquartile range, 64%-82%). Seizure freedom is likely associated with extent of resection.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Astrocytoma; Low-grade glioma; Oligoastrocytoma; Oligodendroglioma; Resection; Seizure; Surgery

Mesh:

Year:  2017        PMID: 28673890     DOI: 10.1016/j.wneu.2017.06.144

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  4 in total

1.  Extent of resection and survival for oligodendroglioma: a U.S. population-based study.

Authors:  Connor J Kinslow; Andrew L A Garton; Ali I Rae; Logan P Marcus; Christopher M Adams; Guy M McKhann; Michael B Sisti; E Sander Connolly; Jeffrey N Bruce; Alfred I Neugut; Adam M Sonabend; Peter Canoll; Simon K Cheng; Tony J C Wang
Journal:  J Neurooncol       Date:  2019-08-12       Impact factor: 4.130

2.  Postoperative epilepsy and survival in glioma patients: a nationwide population-based cohort study from 2009 to 2018.

Authors:  Mirketa Marku; Birthe Krogh Rasmussen; Federica Belmonte; Elisabeth Anne Wreford Andersen; Christoffer Johansen; Pernille Envold Bidstrup
Journal:  J Neurooncol       Date:  2022-01-28       Impact factor: 4.130

3.  Seizures in patients with IDH-mutated lower grade gliomas.

Authors:  Louise Carstam; Isabelle Rydén; Asgeir Store Jakola
Journal:  J Neurooncol       Date:  2022-10-18       Impact factor: 4.506

4.  Functional Outcomes and Health-Related Quality of Life Following Glioma Surgery.

Authors:  Philip C De Witt Hamer; Philip C De Witt Hamer; Martin Klein; Shawn L Hervey-Jumper; Jeffrey S Wefel; Mitchel S Berger
Journal:  Neurosurgery       Date:  2021-03-15       Impact factor: 4.654

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.